[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fC33r1BCi-6f438u9bp8czMeWVxeQZCuwQd4Yf8c7do0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Azienda Ospedaliero Universitaria Maggiore della Carita",[4],53,false,11,4,21007,1,42,[14,16,18,21,23,26,28,30],{"name":15,"count":9},"Obesity",{"name":17,"count":9},"Obesity, Childhood",{"name":19,"count":20},"Coronary Artery Disease",3,{"name":22,"count":20},"Myocardial Infarction",{"name":24,"count":25},"Diabetes Mellitus, Type 2",2,{"name":27,"count":25},"Pediatric Obesity",{"name":29,"count":25},"Surgery",{"name":31,"count":11},"Cancer",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06336187","European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)","2024-12","molecular investigation",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,70,123,145,163,190,215,233,259,277,303,321,346,376,394,412,439],{"intervention":37,"totalTrials":11,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":59},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[],{"trials":56,"activeCount":50},[],{"trials":58,"activeCount":50},[],{"trials":60,"activeCount":11,"soonestReadout":36},[61],{"nctId":34,"briefTitle":35,"status":62,"phases":63,"primaryCompletion":36,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"RECRUITING",[],"2030-12","2018-06-01",400,[68],"Renal Cell Carcinoma",[37],{"intervention":71,"totalTrials":20,"cells":72},"Placebos",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":121},{"trials":74,"activeCount":50},[],{"trials":76,"activeCount":50},[],{"trials":78,"activeCount":50},[],{"trials":80,"activeCount":50},[],{"trials":82,"activeCount":50},[83,98,108],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":96},"NCT03283813","ZIMBA: Clinical Trial in Paediatric Obesity","COMPLETED",[43],"2023-12-31","2024-03-10","2018-02-05",56,[17,93,94,95],"Insulin Resistance","Zinc Deficiency","Inositol",[71,97],"Myoinositol",{"nctId":99,"briefTitle":100,"status":86,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT03261466","BIFI-OBESE: Clinical Trial in Paediatric Obesity",[43],"2017-10-30","2013-11-20",100,[17],[107,71],"Bifidobacterium breve BR03 and Bifidobacterium breve B632",{"nctId":109,"briefTitle":110,"status":86,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":120},"NCT03219931","NEOBIFI: Clinical Trial for the Prevention and\u002For Reduction of the Incidence of Colics in Infants",[43],"2017-07-31","2013-10-01",320,[116,117,118,119],"Colic, Infantile","Probiotic","Gut Microbiome","Bifidobacterium Breve",[107,71],{"trials":122,"activeCount":50},[],{"intervention":107,"totalTrials":25,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":143},{"trials":126,"activeCount":50},[],{"trials":128,"activeCount":50},[],{"trials":130,"activeCount":50},[],{"trials":132,"activeCount":50},[],{"trials":134,"activeCount":50},[135,139],{"nctId":99,"briefTitle":100,"status":86,"phases":136,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":137,"interventions":138},[43],[17],[107,71],{"nctId":109,"briefTitle":110,"status":86,"phases":140,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":141,"interventions":142},[43],[116,117,118,119],[107,71],{"trials":144,"activeCount":50},[],{"intervention":97,"totalTrials":11,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":161},{"trials":148,"activeCount":50},[],{"trials":150,"activeCount":50},[],{"trials":152,"activeCount":50},[],{"trials":154,"activeCount":50},[],{"trials":156,"activeCount":50},[157],{"nctId":84,"briefTitle":85,"status":86,"phases":158,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":159,"interventions":160},[43],[17,93,94,95],[71,97],{"trials":162,"activeCount":50},[],{"intervention":164,"totalTrials":11,"cells":165},"Escitalopram",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":188},{"trials":167,"activeCount":50},[],{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[],{"trials":173,"activeCount":50},[],{"trials":175,"activeCount":50},[176],{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT00967408","Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients","UNKNOWN",[43],"2010-07","2011-10","2009-07",200,[186],"Stroke",[164],{"trials":189,"activeCount":50},[],{"intervention":191,"totalTrials":11,"cells":192},"Intracoronary administration of an abciximab bolus during primary PCI",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":213},{"trials":194,"activeCount":50},[],{"trials":196,"activeCount":50},[],{"trials":198,"activeCount":50},[],{"trials":200,"activeCount":50},[],{"trials":202,"activeCount":50},[203],{"nctId":204,"briefTitle":205,"status":86,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":211},"NCT01757457","Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention",[43],"2008-04","2006-04",89,[22],[191,212],"Intravenous administration of an abciximab bolus during primary PCI",{"trials":214,"activeCount":50},[],{"intervention":212,"totalTrials":11,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":50},[],{"trials":220,"activeCount":50},[],{"trials":222,"activeCount":50},[],{"trials":224,"activeCount":50},[],{"trials":226,"activeCount":50},[227],{"nctId":204,"briefTitle":205,"status":86,"phases":228,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":229,"interventions":230},[43],[22],[191,212],{"trials":232,"activeCount":50},[],{"intervention":234,"totalTrials":11,"cells":235},"omega-3 supplementation",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":255,"NA":257},{"trials":237,"activeCount":50},[],{"trials":239,"activeCount":50},[],{"trials":241,"activeCount":50},[],{"trials":243,"activeCount":50},[244],{"nctId":245,"briefTitle":246,"status":86,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT03911843","Omega-3 and Vitamin D Supplements in Childhood T1D",[41,42],"2018-12-31","2017-01-01",64,[252],"Type 1 Diabetes Mellitus",[234,254],"Vitamin D supplementation",{"trials":256,"activeCount":50},[],{"trials":258,"activeCount":50},[],{"intervention":254,"totalTrials":11,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":273,"NA":275},{"trials":262,"activeCount":50},[],{"trials":264,"activeCount":50},[],{"trials":266,"activeCount":50},[],{"trials":268,"activeCount":50},[269],{"nctId":245,"briefTitle":246,"status":86,"phases":270,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":271,"interventions":272},[41,42],[252],[234,254],{"trials":274,"activeCount":50},[],{"trials":276,"activeCount":50},[],{"intervention":278,"totalTrials":11,"cells":279},"Aspirin 100mg",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":299,"NA":301},{"trials":281,"activeCount":50},[],{"trials":283,"activeCount":50},[],{"trials":285,"activeCount":50},[],{"trials":287,"activeCount":50},[288],{"nctId":289,"briefTitle":290,"status":179,"phases":291,"primaryCompletion":88,"completion":88,"start":292,"enrollment":293,"conditions":294,"interventions":297},"NCT05554822","Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study",[42],"2021-06-14",574,[295,296],"Left Atrial Appendage Occlusion","Antiplatelet Therapy",[278,298],"Aspirin 100 mg OD plus clopidogrel 75 mg OD",{"trials":300,"activeCount":50},[],{"trials":302,"activeCount":50},[],{"intervention":298,"totalTrials":11,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":317,"NA":319},{"trials":306,"activeCount":50},[],{"trials":308,"activeCount":50},[],{"trials":310,"activeCount":50},[],{"trials":312,"activeCount":50},[313],{"nctId":289,"briefTitle":290,"status":179,"phases":314,"primaryCompletion":88,"completion":88,"start":292,"enrollment":293,"conditions":315,"interventions":316},[42],[295,296],[278,298],{"trials":318,"activeCount":50},[],{"trials":320,"activeCount":50},[],{"intervention":322,"totalTrials":11,"cells":323},"Adenosine",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":342,"NA":344},{"trials":325,"activeCount":50},[],{"trials":327,"activeCount":50},[],{"trials":329,"activeCount":50},[],{"trials":331,"activeCount":50},[332],{"nctId":333,"briefTitle":334,"status":86,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":341},"NCT01148147","Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty",[42],"2010-08","2009-11",260,[340],"Coronary Angioplasty",[322],{"trials":343,"activeCount":50},[],{"trials":345,"activeCount":50},[],{"intervention":347,"totalTrials":11,"cells":348},"PEAPROSTIL 600 + Tamsulosin 0.4 mg",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":350,"activeCount":50},[],{"trials":352,"activeCount":50},[],{"trials":354,"activeCount":50},[],{"trials":356,"activeCount":50},[],{"trials":358,"activeCount":50},[],{"trials":360,"activeCount":50},[361],{"nctId":362,"briefTitle":363,"status":179,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":373},"NCT06181175","Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial",[44],"2024-10-30","2025-04-30","2021-10-01",250,[370,371,372],"Benign Prostatic Hyperplasia","Urinary Obstruction","Lower Urinary Tract Symptoms",[347,374,375],"Tamsulosin 0.4 mg","PEAPROSTIL 600 mg",{"intervention":374,"totalTrials":11,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":379,"activeCount":50},[],{"trials":381,"activeCount":50},[],{"trials":383,"activeCount":50},[],{"trials":385,"activeCount":50},[],{"trials":387,"activeCount":50},[],{"trials":389,"activeCount":50},[390],{"nctId":362,"briefTitle":363,"status":179,"phases":391,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":392,"interventions":393},[44],[370,371,372],[347,374,375],{"intervention":375,"totalTrials":11,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":397,"activeCount":50},[],{"trials":399,"activeCount":50},[],{"trials":401,"activeCount":50},[],{"trials":403,"activeCount":50},[],{"trials":405,"activeCount":50},[],{"trials":407,"activeCount":50},[408],{"nctId":362,"briefTitle":363,"status":179,"phases":409,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":410,"interventions":411},[44],[370,371,372],[347,374,375],{"intervention":413,"totalTrials":11,"cells":414},"Edoxaban",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":416,"activeCount":50},[],{"trials":418,"activeCount":50},[],{"trials":420,"activeCount":50},[],{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[427],{"nctId":428,"briefTitle":429,"status":179,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":437},"NCT06285942","EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation",[44],"2025-01-31","2024-02-01",168,[435,436],"Atrial Fibrillation","Fragility",[413,438],"No Edoxaban",{"intervention":438,"totalTrials":11,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":442,"activeCount":50},[],{"trials":444,"activeCount":50},[],{"trials":446,"activeCount":50},[],{"trials":448,"activeCount":50},[],{"trials":450,"activeCount":50},[],{"trials":452,"activeCount":50},[453],{"nctId":428,"briefTitle":429,"status":179,"phases":454,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":455,"interventions":456},[44],[435,436],[413,438]]